Chesley Taft & Associates LLC Has $24.59 Million Stock Holdings in Thermo Fisher Scientific Inc. $TMO

Chesley Taft & Associates LLC grew its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 3.6% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 42,442 shares of the medical research company’s stock after purchasing an additional 1,469 shares during the period. Thermo Fisher Scientific makes up 1.0% of Chesley Taft & Associates LLC’s investment portfolio, making the stock its 28th biggest holding. Chesley Taft & Associates LLC’s holdings in Thermo Fisher Scientific were worth $24,593,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently made changes to their positions in TMO. Capital World Investors raised its stake in Thermo Fisher Scientific by 7.4% during the 3rd quarter. Capital World Investors now owns 10,285,145 shares of the medical research company’s stock worth $4,988,132,000 after buying an additional 706,572 shares during the period. Franklin Resources Inc. grew its stake in Thermo Fisher Scientific by 21.0% in the third quarter. Franklin Resources Inc. now owns 5,925,671 shares of the medical research company’s stock valued at $2,874,069,000 after acquiring an additional 1,028,125 shares during the period. Bank of New York Mellon Corp increased its holdings in shares of Thermo Fisher Scientific by 54.7% during the third quarter. Bank of New York Mellon Corp now owns 3,571,857 shares of the medical research company’s stock valued at $1,732,422,000 after acquiring an additional 1,262,967 shares in the last quarter. Massachusetts Financial Services Co. MA lifted its holdings in shares of Thermo Fisher Scientific by 25.4% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 2,936,998 shares of the medical research company’s stock worth $1,424,503,000 after purchasing an additional 594,218 shares in the last quarter. Finally, Fisher Asset Management LLC grew its position in Thermo Fisher Scientific by 1.2% in the 3rd quarter. Fisher Asset Management LLC now owns 2,721,101 shares of the medical research company’s stock valued at $1,319,789,000 after purchasing an additional 31,298 shares during the period. 89.23% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Thermo Fisher Scientific

In other news, CEO Marc N. Casper sold 5,000 shares of the firm’s stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $512.40, for a total transaction of $2,562,000.00. Following the completion of the sale, the chief executive officer directly owned 123,925 shares of the company’s stock, valued at $63,499,170. This trade represents a 3.88% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Gianluca Pettiti sold 400 shares of the business’s stock in a transaction dated Monday, February 9th. The stock was sold at an average price of $541.20, for a total transaction of $216,480.00. Following the completion of the transaction, the executive vice president directly owned 20,752 shares in the company, valued at $11,230,982.40. This trade represents a 1.89% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Company insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Stock Down 3.1%

Thermo Fisher Scientific stock opened at $473.83 on Friday. Thermo Fisher Scientific Inc. has a fifty-two week low of $385.46 and a fifty-two week high of $643.99. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.53 and a current ratio of 1.89. The firm’s 50-day simple moving average is $530.10 and its 200 day simple moving average is $547.79. The stock has a market cap of $176.02 billion, a PE ratio of 26.71, a price-to-earnings-growth ratio of 2.73 and a beta of 0.96.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings data on Thursday, January 29th. The medical research company reported $6.57 EPS for the quarter, beating the consensus estimate of $6.45 by $0.12. Thermo Fisher Scientific had a net margin of 15.05% and a return on equity of 16.92%. The firm had revenue of $12.22 billion during the quarter, compared to analyst estimates of $11.95 billion. During the same quarter last year, the business posted $6.10 EPS. The company’s revenue for the quarter was up 7.2% on a year-over-year basis. Research analysts predict that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 15th. Shareholders of record on Friday, March 13th will be given a $0.47 dividend. This is an increase from Thermo Fisher Scientific’s previous quarterly dividend of $0.43. This represents a $1.88 annualized dividend and a yield of 0.4%. The ex-dividend date of this dividend is Friday, March 13th. Thermo Fisher Scientific’s payout ratio is presently 10.60%.

Analysts Set New Price Targets

Several research analysts have weighed in on the stock. TD Cowen lowered their price objective on shares of Thermo Fisher Scientific from $696.00 to $683.00 and set a “buy” rating on the stock in a report on Friday, January 30th. Wall Street Zen upgraded shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a report on Saturday, February 28th. UBS Group reiterated a “neutral” rating and set a $615.00 price target on shares of Thermo Fisher Scientific in a research note on Friday, January 30th. DZ Bank initiated coverage on Thermo Fisher Scientific in a report on Friday. They set a “buy” rating and a $610.00 price objective for the company. Finally, The Goldman Sachs Group started coverage on Thermo Fisher Scientific in a report on Tuesday, December 9th. They issued a “buy” rating and a $685.00 target price on the stock. One equities research analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $632.50.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.